Evidence map›Paper›PMID 40837011›Full record

ArticleFrontiers in oncology2025

A phase I study of S-1 and cisplatin with concurrent hypofractionated carbon-ion radiotherapy for patients with stage III non-small cell lung cancer.

Yosuke Miura, Nobuteru Kubo, Noriaki Sunaga, Naoko Okano, Hiroaki Tsurumaki, Hidemasa Kawamura, Reiko Sakurai, Toshitaka Maeno, Takeshi Hisada, Tatsuya Ohno

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yosuke MiuraDepartment of Respiratory Medicine, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
Nobuteru KuboGunma University Heavy Ion Medical Center, Maebashi, Gunma, Japan.
Noriaki SunagaDepartment of Respiratory Medicine, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
Naoko OkanoGunma University Heavy Ion Medical Center, Maebashi, Gunma, Japan.
Hiroaki TsurumakiDepartment of Respiratory Medicine, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
Hidemasa KawamuraGunma University Heavy Ion Medical Center, Maebashi, Gunma, Japan.
Reiko SakuraiDepartment of Medical Oncology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
Toshitaka MaenoDepartment of Respiratory Medicine, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
Takeshi HisadaGunma University Graduate School of Health Sciences, Maebashi, Gunma, Japan.
Tatsuya OhnoGunma University Heavy Ion Medical Center, Maebashi, Gunma, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: We conducted a phase I study to evaluate the recommended dose of S-1 in combination with cisplatin (SP) and concurrent carbon ion radiotherapy (CIRT) in patients with stage III locally advanced non-small cell lung cancer (LA-NSCLC). Materials and methods: S-1 was administered orally twice daily after a meal for 14 consecutive days, and cisplatin was administered on days 1 and 8. The dose of each drug in this study was planned as follows: level 0, S-1-30 mg/m Results: Six patients were enrolled in this study. At level 1, one patient experienced grade 3 elevated alanine aminotransferase and aspartate aminotransferase levels, which is regarded as a dose-limiting toxicity. This event improved immediately. Five patients developed grade 2 esophagitis. In three of the five patients, symptoms such as pain and dysphagia due to esophagitis recurred several months after resolution of the acute esophagitis that occurred during irradiation. None of the patients experienced adverse events of ≥grade 3. Thus, level 1 was determined to be the recommended dose. Conclusion: Chemotherapy with SP and concurrent CIRT is feasible and well-tolerated in patients with Stage III LA-NSCLC.

Indexed as

carbon-ion radiotherapyclinical trialconcurrent chemoradiotherapynon-small cell lung cancerplatinum-based chemotherapy

Identifiers

PMID40837011
PMCPMC12361162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.